403 results about "Allergen" patented technology

The invention discloses a tear total IGE detection method and system based on multi-modal data fusion. The method comprises the following steps: acquiring ocular surface images, physiological parameters and environmental allergen data, and acquiring historical medical data from a hospital information system; preprocessing and feature extraction are performed, patient symptom description is analyzed in combination with a natural language processing technology, and related image block features are recognized; adjusting a space-time attention weight based on frequency domain analysis and transfer learning, inputting a lightweight Transform model, and predicting a tear total IgE concentration and an allergy risk score; whether a trace tear sampling program is started or not is judged, and the actually measured concentration of total tear IgE is detected through a disposable micro-fluidic chip; and integrating all information by using a Bayesian adaptive filtering algorithm to determine the total tear IgE level. By implementing the method provided by the invention, the sampling amount is extremely small, the detection time is short, the environmental interference can be dynamically corrected, and the absolute concentration value is output, so that the dual requirements of clinical precise diagnosis and treatment and home monitoring are met.

The invention discloses a lactobacillus rhamnosus strain with antiallergic activity and a preparation method thereof, the strain is lactobacillus rhamnosus Lrn-PG-06, the classification name of the strain is Lactobacillus rhamnosus, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.3077, the preservation time is March 21, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.3077, and the preservation number is CGMCC No.3077. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus Lrn-PG-06 strain is high in acid resistance, alkali resistance and cholate resistance, high in simulated gastrointestinal fluid resistance and high in oxidation resistance, has the advantage of resisting allergy, and solves the problems that at present, allergic diseases are mainly treated by drugs or are prevented from being in contact with allergens in the environment and food, but due to the fact that the drugs are large in toxic and side effects, the allergens cannot be in contact with the allergens in the environment and food. And allergens causing anaphylaxis are difficult to determine, so that allergic diseases are difficult to treat or prevent.

The invention relates to the technical field of atlas generation, in particular to a children cross-allergen risk dynamic atlas generation system, which comprises the following steps: firstly, determining sensitivity indexes according to immune response conditions of each type of allergens in all allergy detection processes; according to the similarity of each allergen and other allergens in two dimensions of allergen protein structure and IgE level, combining the sensitivity index, and comprehensively representing the cross reaction risk index of each allergen in each allergy detection process; then comprehensively determining the cross-allergy risk degree of various allergens in each season period according to the increasing trend of the cross-allergy risk index curve in each season period and the overall size of the cross-allergy risk index in combination with the characteristic that the cross-allergy reaction possibly caused by the season change is dynamically changed; and the cross allergen risk dynamic map generated in real time according to the cross allergen risk degree is more accurate.

The invention discloses a screening method of allergen substances in a carthamin yellow injection, a verification method of the allergen substances in the carthamin yellow injection, a detection method of the allergen substances in the carthamin yellow injection and a production process of the carthamin yellow injection. The screening method of the allergen substances in the carthamin yellow injection comprises the following steps: S1, extracting components in the carthamin yellow injection; s2, separating and screening components in the extract by adopting a high performance liquid chromatography-ultraviolet detection-mass spectrum and human serum albumin combined detection technology; and S3, screening out a substance which can be combined with the HSA, and determining the substance as a sensitization hapten substance which has sensitization potential. The invention aims to detect that the 6-hydroxykaempferol-3-rutin-6-glucoside has HAS binding characteristic, hapten attribute and sensitization potential, and can provide basis for process improvement of carthamin yellow injection and reduce the sensitization risk in clinical application.

The invention provides agonistic TNFR2 antibodies and antigen-binding fragments thereof and encompasses the use of these antibodies as therapeutics to promote the proliferation of regulatory T cells (T-reg) for the treatment of immunological diseases. Antibodies of the invention can be used to potentiate the T-reg-mediated deactivation of self- and allergen-reactive T- and B-lymphocytes, and can thus be used to treat a wide variety of indications, including autoimmune diseases, allergic reactions, asthma, graft-versus-host disease, and allograft rejection, among others.

The present invention relates to the technical field of test kits, and specifically discloses an allergen detection kit comprising, arranged in order from top to bottom, a front cover, a partition, a test box body, a deflection membrane, a cotton strip, and a rear cover. The front cover is provided with a sample loading hole, which is connected to a plurality of buckle grooves. The partition is provided with a plurality of openings. The test box body is provided with a plurality of test slots. The test slots, openings, and buckle grooves enclose a test chamber for accommodating a test membrane strip. The front cover is provided with an overflow channel connecting one side of the buckle groove. The partition and the test box body are provided with a first through hole and a second through hole, respectively, below the overflow channel. The test slot is provided with a third through hole and a fourth through hole, respectively, on the side proximal to and distal to the second through hole. The second and third through holes are sealed and connected at the bottom of the test box body by a deflection membrane. The cotton strip is provided below the fourth through hole. The test box body is provided with a gas hole. The present invention has a simple structure, high detection efficiency, and can achieve simultaneous detection of multiple allergens.

Provided are a method for preparing a protein marker for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization in infants, and a method for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization using said protein marker.　More specifically, the method for preparing a protein marker for predicting the risk of developing atopic dermatitis includes recovering at least one kind of protein selected from FGG, FGA, FGB, FN1, IGHG1, IGHG2, IGHG3, IGHG4, C3, C4B, C7, CFB, CFH, EPX, CLC, RNASE3, RNASE2 and PRG2 from a sample collected from the skin of an infant subject.

The present invention provides a technology for identifying or quantifying allergens such as pollen, mold, and mites.　This detection device uses a plurality of semiconductor sensors. With respect to the same gas component, the plurality of semiconductor sensors indicate relatively different response characteristics. The detection device: acquires signal patterns detected by the plurality of semiconductor sensors; identifies or quantifies an allergen from the plurality of signal patterns; and outputs a result of identification or quantification.

The present invention includes compositions, including epitope megapools, and methods for detecting the presence of cow milk allergen(s), specifically T cell epitopes for T cells responsive to one or more cow milk peptides or proteins comprising, consisting of, or consisting essentially of: one or more peptides or proteins selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081), or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein comprising one or more amino acid sequences selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such protein(s) or peptide(s).

The invention discloses a beta-alanine sustained release preparation, the sustained release preparation takes beta-alanine as a core material and a non-allergen wall material as an embedding material, and the non-allergen wall material is pea protein and / or ethyl cellulose. The sustained-release preparation disclosed by the invention is appropriate in release rate, not only can effectively relieve side effects generated after taking beta-alanine, but also can meet the health-care function of improving athletic ability in a short time, so that the beta-alanine sustained-release preparation disclosed by the invention can be widely applied to foods and / or health-care products.

The present invention provides a composition for use in the prevention and / or treatment of a viral infection in an individual wherein the composition comprises Bifidobacterium longum subsp. Infantis and a mixture of HMO consisting of 2 '-fucosyllactose (2FL), difucosyllactose (DFL), lactose-N-tetraose (LNT), 6'-sialyllactose (6SL), 3 '-sialyllactose (3SL), and 3-fucosyllactose (3FL). The present invention also provides compositions for use in preventing and / or reducing the risk of allergen sensitization, preventing and / or reducing the risk of developing respiratory disorders in an individual, and / or preventing and / or reducing the risk of developing asthma in an individual.

The invention discloses manganese-based Prussian blue-polyacrylic acid / polyvinyl alcohol hydrogel for preventing and treating allergic rhinitis. Monodisperse manganese-based Prussian blue nanoparticles synthesized by taking polyacrylic acid as a template are stably immobilized in a polyacrylic acid / polyvinyl alcohol hydrogel matrix. The obtained composite hydrogel membrane has the following prominent advantages: the composite hydrogel membrane has excellent hydrogel characteristics, including controllable membrane thickness, good tissue adhesion and air permeability; reliable biocompatibility and safety are shown; allergen permeation is effectively blocked through a physical barrier effect; prussian blue is continuously released in the slow-release degradation process, active oxygen free radicals are remarkably removed, and the powerful anti-inflammatory effect is achieved. Due to the synergistic effect of double mechanisms of protection and treatment, the material has important clinical application value and development potential in the fields of prevention and treatment of allergic rhinitis.

The present invention relates to a composition comprising a Bifidobacterium longum transitional microorganism and a mixture of human milk oligosaccharides (HMOs) consisting of 2'-fucosyllactose (2'-FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), and 3'-sialyllactose (3SL), and optionally lacto-N-fucopentaose I (LNFP-I), 3- fucosyllactose (3-FL) and / or lacto-N-neotetraose (LNnT), wherein the Bifidobacterium longum transitional microorganism has an Average Nucleotide Identity (ANI) of at least 98% with CNCM I-5942. The invention also relates to the use of the composition for preventing, reducing the risk of and / or treating an infection in a subject. The invention also provides the composition for use in promoting a long-term immune benefit in a subject, preventing and / or reducing the risk of allergen sensitisation, preventing and / or reducing the risk of developing a respiratory condition in a subject, and / or preventing and / or reducing the risk of developing asthma in a subject.

The invention provides a portunus trituberculatus SCP antigen, antibody, kit and application, and belongs to the technical field of allergen detection. The antigen of the portunus trituberculatus SCP comprises an antigen epitope peptide of the portunus trituberculatus SCP and a carrier protein, and the amino acid sequence of the antigen epitope peptide of the portunus trituberculatus SCP is as shown in SEQ ID NO. 14. The antigen epitope peptide of the antigen portunus trituberculatus SCP has a relatively stable structure before and after thermal processing, the detection limit of an antibody prepared from the antigen for detecting a crustacean allergen is 0.32 mu g / mL, the quantitation limit is 1.06 mu g / mL, the crustacean allergen can be specifically detected, and the antibody can be used for detecting the crustacean allergen. In addition, when the antibody is used for detecting the crustacean allergen, the accuracy is good, the matrix interference resistance and the precision are high, and the high detection effect on the crustacean allergen in food processed at high temperature can still be kept.

The invention relates to the technical field of food, in particular to a preparation method of low-sensitization hydrolyzed whey protein nanoscale microcapsule powder, which comprises the following steps: S1, preparing a whey protein solution, performing microfiltration, and treating with cysteine hydrochloride; s2, trypsin hydrolysis; s3, inactivating and cooling; s4, adding chymotrypsin, and synchronously applying ultrasonic waves; s5, bromelain is added, ultrafiltration is performed, and peptide fragments are collected; s6, preparing a capsule wall solution; s7, adopting a micro-fluidic chip to form a nano emulsion; s8, the mixture is added into a CaCl2 solution to be stirred, multi-layer self-assembly is conducted, and micro-capsule particles are obtained; and S9, carrying out ultrahigh-pressure micro-jet homogenization, vacuum freeze drying and low-temperature plasma assisted grinding on the micro-capsule particles to obtain the nano-scale micro-capsule powder. The stability of active ingredients is maintained through multi-enzyme cooperation and ultrasonic-assisted efficient elimination of allergens, multi-layer nano-embedding under microfluidic control and low-temperature plasma grinding, and the limitations of low single enzymolysis efficiency, insufficient embedding rate and thermal denaturation risk in the prior art are overcome.

The embodiment of the invention discloses a production quality control method and device for a vegetable protein beverage and a medium, and relates to the technical field of vegetable protein beverages, and the method comprises the steps: obtaining production line parameters of a current beverage production line, and carrying out allergen cross contact risk analysis based on the production line parameters, determining at least one target allergen quality inspection node in the current beverage production line; collecting allergen quality inspection data of each target allergen quality inspection node in real time to determine a real-time beverage quality index parameter corresponding to each target allergen quality inspection node; when preset conditions are met, according to the real-time beverage quality index parameters and pre-obtained real-time production line parameters, tracing analysis is conducted on allergen standard exceeding reasons, standard exceeding evaluation data of target allergen quality inspection nodes are determined, and the allergen quality inspection nodes are determined through a pre-constructed allergen component control knowledge base according to the standard exceeding evaluation data. And a corresponding production control strategy is determined, and production quality optimization is carried out through the production control strategy.

The invention relates to a consumable-free air allergen detection device and method based on fusion of ultraviolet fluorescence and scattered light, and the device comprises an air path system, an optical detection module, a self-cleaning electrode and an auxiliary module; the gas path system comprises a spiral gas path; the optical detection module comprises an ultraviolet fluorescence unit and a dual-wavelength scattering unit; the ultraviolet fluorescence unit comprises an ultraviolet LED (Light Emitting Diode) and a 340nm band-pass optical filter; the dual-wavelength scattering unit comprises a 650nm laser, a 850nm VCSEL (Vertical Cavity Surface Emitting Laser) and a scattering detector; the auxiliary module comprises a temperature and humidity sensor; the spiral gas circuit is located on a center shaft of the device. An inclination angle of 8 degrees is formed between the ultraviolet LED and the central axis of the spiral gas path; the 340nm band-pass optical filter is positioned right opposite to the ultraviolet LED and is coaxial with the ultraviolet LED; a 650nm laser is mounted in a 15-degree direction in front of the spiral gas path; the 850nm VCSE is mounted in the 90-degree direction of the side direction of the spiral gas path; the scattering detector integrates a forward 15-degree channel and a lateral 90-degree channel. According to the invention, small-size, consumable-free and high-precision real-time detection of protein and allergen in air can be realized.

The augmented-reality automated allergy office method comprises initially delivering a trace amount of a first allergen to a first test site via a multiple test applicator as the multiple test applicator delivers a trace amount of a second allergen to a second test site during allergen deposition. The multiple test applicator is cooperatively engageable with a fluid tray during allergen loading and with the patient's skin during allergen deposition. Then, capturing a first image of the first and second test site using a smart phone or tablet computer. Subsequently, capturing a second image of the first and second test site within 15 to 20 minutes after allergen deposition. And finally, developing a computer-generated treatment plan using machine learning for the patient with an allergy condition that is a step-by-step procedure, the computer-generated treatment plan being stored in a medical database for treating patients with the allergy condition.

The invention relates to a method for reducing the anaphylaxis of natural latex by multi-enzyme cascade catalysis of rubber protein. The invention relates to the technical field of catalysis of rubber protein hydrolysis, in particular to a method for reducing the anaphylaxis of natural latex by thoroughly hydrolyzing rubber protein through multi-enzyme cascade catalysis. The method for reducing the anaphylaxis of the natural latex by catalyzing the rubber protein through the synergistic effect of multiple enzymes from the perspective of industrial production comprises the following steps: adding an enzyme A and an enzyme B into the natural latex for reaction so as to reduce the anaphylaxis of the natural latex, the enzyme A is alkaline protease; and the B enzyme is at least one of aminopeptidase, carboxypeptidase B, carboxypeptidase A and carboxypeptidase Y. According to the method disclosed by the invention, the enzyme A-endopeptidase and the enzyme B-exopeptidase are subjected to multi-enzyme-stage combined treatment and concerted catalysis, so that the enzyme A-endopeptidase and the enzyme B-exopeptidase are completely hydrolyzed or are completely hydrolyzed into more amino acid substances and short-chain peptides (oligopeptides) as far as possible, and the amino acid substances and the short-chain peptides (oligopeptides) are retained in latex. Protein is highly hydrolyzed into amino acid with higher safety, so that the possibility of I-type anaphylactic reaction caused by protein allergens is greatly reduced or even eliminated.

The invention discloses a preparation method and application of a cat main allergen FEL-1 nano antibody FEL-1-Nb, and relates to the technical field of antibody preparation, and the preparation method comprises the following steps: preparing an immunogen; animal immunization and library construction; constructing and panning a phage display library; screening and identifying positive clone; and expression and purification of the nano antibody: cloning the positively cloned VHH gene to an expression vector such as a pET series, transforming an expression strain such as escherichia coli BL21 (DE3), carrying out IPTG induced expression, and purifying through an inclusion body purification method to obtain a high-purity nano antibody protein. The nano antibody FEL-1-Nb provided by the invention can be specifically bound with a cat main allergen FEL-1 protein, the unique amino acid sequence of the nano antibody FEL-1-Nb is shown as SEQIDNO: 1, high-affinity binding with the FEL-1 protein is ensured, the positive clone binding rate is high through phage display panning and ELISA verification, the phage recovery rate after the third round of panning is increased by more than 1000 times compared with the first round of panning, and the positive clone binding rate is higher than that of the first round of panning. Therefore, the nano antibody has excellent targeted recognition capability.

The present invention aims to treat hay fever by providing water from which pollen (an allergen) has been removed using the pollen treatment facility C of the present invention. [Solution] In a water treatment system consisting of a water tower B, a water treatment plant D, a sand filtration area E, and a water distribution reservoir F, a pollen treatment facility is provided to remove pollen from the river water 1 supplied to the water treatment plant D.

A kit (100) and method (200) are provided for administering an active ingredient (112) to a subject to elicit a response. The kit comprises a first container (110) with an active ingredient (112) and a second container (120) with an adjuvant (122). The containers permit the ingredients to be admixed to form a compounded preparation for delivery into the subject's tissue. The active ingredient can comprise an allergen. The kit can also include temperature control and mixing components, potentially involving a third container (130). The method comprises providing the kit (100), admixing the ingredients, and injecting the compounded form into the subject's tissue such as a lymph node. The injection can be monitored and repeated. The approach can elicit various responses such as desensitization according to the type of active ingredient used. Overall, the kit (100) and method (200) provide targeted delivery of active ingredients to efficiently provoke a localized response in the subject.

The invention relates to the technical field of allergen proteins and antigen epitopes, and discloses an Antarctic krill allergen and an identification method and application of the Antarctic krill allergen, the Antarctic krill allergen and the antigen epitopes are used for identifying the Antarctic krill allergen and the antigen epitopes, and the identification method comprises the steps of Antarctic krill crude protein extraction, Antarctic krill allergen screening and identification. Extracting an antarctic krill map and verifying allergens; analyzing the homology of the euphausia superba and analyzing the conformation of tropomyosin of the euphausia superba; carrying out euphausia superba tropomyosin epitope analysis; and allergens and epitopes of the euphausia superba are applied. According to the invention, the antarctic krill allergen is identified as tropomyosin, eight antigen epitopes of the antarctic krill tropomyosin allergen are ascertained, the stability change rule in the hot working process is analyzed by utilizing the identified antarctic krill allergen and antigen epitopes, and the result shows that the stability of the antarctic krill allergen is greatly improved under the processing condition of 140 DEG C or below. And the conformation of the tropomyosin of the euphausia superba and the binding capacity of the tropomyosin with protein immune globulin E or immune globulin G are kept stable.

The invention relates to an allergen detection task generation method, a detection method and a sample analyzer. The method comprises the following steps: identifying detection information of a detection sheet, and determining an allergen detection type; according to the allergen detection type, a detection work order used for indicating detection items is displayed, and the detection items comprise a fixed detection item group and a to-be-selected detection item group; based on a selection instruction of a user, determining a plurality of to-be-selected detection items corresponding to the detection information from the to-be-selected detection item group, and forming an elastic detection item group; and generating an allergen detection task according to the fixed detection item group, the elastic detection item group and the reference detection item. According to the scheme provided by the invention, the allergen can be subjected to elastic combined detection, and the detection cost of a patient is reduced.

The invention discloses a child allergen confirmation method and system based on online data transmission, and relates to the technical field of data transmission. The method comprises the steps of encrypting and transmitting collected child biological monitoring data to a parent terminal based on an asymmetric key pair, and generating an updated asymmetric key pair; based on the symmetric key, encrypting and transmitting the child biological monitoring data and the input child allergen description data to an analysis terminal, and generating an updated symmetric key; using a child allergen knowledge graph to extract child allergen information of the child allergen description data and the child biological monitoring data, and performing auditing to obtain standard child allergen information; and based on the updated symmetric key, encrypting and transmitting the standard child allergen information to the parent terminal, and checking the standard child allergen information. The problems of data potential safety hazards, key management rigidity and insufficient data processing accuracy in the prior art are solved.

In one embodiment, the present disclosure provides hypoallergenic peanut allergen AraH6 variants, in which at least one epitope recognized by an anti-AraH6 antibody has been altered, thereby reducing or eliminating antibody binding to the peanut allergen. Such hypoallergenic peanut allergen variants retain immunogenicity and can be used in methods for treating and reducing the severity of peanut allergies in subjects (patients) with peanut allergies.

Disclosed are a method for detecting sugi allergen-specific IgE antibodies in a body fluid sample, which can improve the detection value of sugi allergen-specific IgE antibodies, and a kit for use therein. The method comprises the following steps: a removal step for removing non-IgE antibodies such as IgG antibodies from the body fluid sample; a reaction step for contacting the antibody-removed body fluid sample obtained in the removal step with a reaction well on a substrate having a reaction well, thereby forming a complex between the allergen and the allergen-specific IgE antibody; the reaction well comprising a region immobilizing the sugi allergen and regions immobilizing one or more allergens other than the sugi allergen; and a detection step for detecting the complex between the sugi allergen and the sugi allergen-specific IgE antibody obtained in the reaction step.

This invention provides a peanut allergen peptide, its screening method, and its application. Phage display technology is used to screen for conformational epitopes of Ara h5 and Ara h8 proteins. Polyclonal IgE and IgG antibodies against the target proteins are prepared by immunizing BALB / c mice with Ara h5 and Ara h8 proteins as antigens. ELISA and dotted immunoblotting detection revealed that the titers of polyclonal IgG and IgE against Ara h5 and Ara h8 proteins were 1:64000 and 1:320, respectively, and the antibodies exhibited specificity. Using the antibodies as targets, phage display technology screened the conformational epitope sequences of Ara h5 protein as WETIYSR and FHWWYLK. The conformational epitopes of Ara h8 protein were FPYMKFV, FPYMKFR, SMFARID, and SFHWWLF.